At a glance

ClinicalIndex Comparison Record

Phase 2Active· 30 enrolled

Drug / intervention

Nivolumab Injection +1 moredrug

Likely dose

Nivolumab Injection 240mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03918252

NCT03918252Phase 2Active

Compare CT.gov

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Apr 17, 2019·Updated Jun 5, 2026

In Brief

A Phase 2 clinical trial evaluating Nivolumab Injection and Ipilimumab Injection for Mesothelioma. Active but no longer recruiting, targeting 30 participants across 3 sites.

Detailed Summary

The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard bi-/tri-modality therapy.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMesothelioma

CountriesUnited States

CollaboratorsBristol-Myers Squibb

Timeline

Phase 2Active

202020212022202320242025202620272028

First PostedApr 2019

Enrollment StartOct 2019

TodayJul 2026

Primary CompletionJun 2027

Study CompletionJun 2028

First PostedApr 17, 2019

Enrollment StartOct 2, 2019

Primary CompletionJun 1, 2027

Study CompletionJun 1, 2028

TodayJul 2, 2026

Enrollment to primary: 7.7 yearsPosted 7.2 years agoPrimary completion in 11 months

Interventions

Nivolumab Injectiondrug

Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).

Ipilimumab Injectiondrug

Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).